NASDAQ:NDRAENDRA Life Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.90 -0.01 (-1.10 %) (As of 06/2/2020 09:44 AM ET) Add Compare Share Today's Range$0.90Now: $0.90▼$0.9150-Day Range$0.65MA: $0.78▼$0.9252-Week Range$0.60Now: $0.90▼$2.25Volume1,235 shsAverage Volume295,575 shsMarket Capitalization$12.99 millionP/E RatioN/ADividend YieldN/ABeta1.8 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingENDRA Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, ENDRA Life Sciences has a potential upside of 570.0% from its current price of $0.90.Amount of Analyst CoverageENDRA Life Sciences has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesENDRA Life Sciences has received 224 “outperform” votes. (Add your “outperform” vote.)Underperform VotesENDRA Life Sciences has received 257 “underperform” votes. (Add your “underperform” vote.)Community SentimentENDRA Life Sciences has received 53.43% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ENDRA Life Sciences and other stocks. Vote “Outperform” if you believe NDRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NDRA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldENDRA Life Sciences does not currently pay a dividend.Dividend GrowthENDRA Life Sciences does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ENDRA Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,400.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 11.40% of the stock of ENDRA Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 7.86% of the stock of ENDRA Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ENDRA Life Sciences are expected to grow in the coming year, from ($0.82) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ENDRA Life Sciences is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ENDRA Life Sciences is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioENDRA Life Sciences has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.89 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NDRA Previous Symbol CUSIPN/A CIK1681682 Webwww.endrainc.com Phone734-335-0468Debt Debt-to-Equity Ratio0.13 Current Ratio2.43 Quick Ratio2.32Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10,000.00 Price / Sales1,299.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book1.57Profitability EPS (Most Recent Fiscal Year)($2.34) Net Income$-13,310,000.00 Net MarginsN/A Return on Equity-528.26% Return on Assets-302.05%Miscellaneous Employees11 Outstanding Shares14,510,000Market Cap$12.99 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:NDRA Rates by TradingView Receive NDRA News and Ratings via Email Sign-up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter. ENDRA Life Sciences (NASDAQ:NDRA) Frequently Asked Questions How has ENDRA Life Sciences' stock been impacted by COVID-19 (Coronavirus)? ENDRA Life Sciences' stock was trading at $1.0029 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NDRA stock has decreased by 10.7% and is now trading at $0.8955. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ENDRA Life Sciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ENDRA Life Sciences. When is ENDRA Life Sciences' next earnings date? ENDRA Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for ENDRA Life Sciences. How were ENDRA Life Sciences' earnings last quarter? ENDRA Life Sciences Inc (NASDAQ:NDRA) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($0.29) EPS for the quarter, hitting the consensus estimate of ($0.29). View ENDRA Life Sciences' earnings history. What price target have analysts set for NDRA? 2 brokerages have issued 12-month target prices for ENDRA Life Sciences' shares. Their forecasts range from $6.00 to $6.00. On average, they expect ENDRA Life Sciences' stock price to reach $6.00 in the next year. This suggests a possible upside of 570.0% from the stock's current price. View analysts' price targets for ENDRA Life Sciences. Has ENDRA Life Sciences been receiving favorable news coverage? News coverage about NDRA stock has been trending very positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ENDRA Life Sciences earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutENDRA Life Sciences. Who are some of ENDRA Life Sciences' key competitors? Some companies that are related to ENDRA Life Sciences include Fc Global Realty (FCRE), electroCore (ECOR), Reshape Lifesciences (RSLS), IRIDEX (IRIX), Helius Medical Technologies (HSDT), Precision Optics (PEYE), Second Sight Medical Products (EYES), CHF Solutions (CHFS), Viveve Medical (VIVE), Vaso (VASO), Digirad (DRAD), ReShape Lifesciences (RSLSD), Guided Therapeutics (GTHP), Nexeon Medsystems (NXNN) and Echo Therapeutics (ECTE). View all competitors. What other stocks do shareholders of ENDRA Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Seanergy Maritime (SHIP), Vaxart (VXRT), Achieve Life Sciences (ACHV), Gilead Sciences (GILD), Gold Standard Ventures (GSV), Gold Standard Ventures (GSV), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Ring Energy (REI) and Ring Energy (REI). Who are ENDRA Life Sciences' key executives? ENDRA Life Sciences' management team includes the following people: Mr. Francois Michelon, Chairman & CEO (Age 53)Mr. David R. Wells, CFO & Sec. (Age 57)Mr. Michael Thornton, Chief Technology Officer (Age 51)Dr. Jonathan Behr Ph.D., Co-FounderMr. Steve Freeman, HR Leader When did ENDRA Life Sciences IPO? (NDRA) raised $10 million in an IPO on Friday, February 3rd 2017. The company issued 2,000,000 shares at $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO. What is ENDRA Life Sciences' stock symbol? ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA." Who are ENDRA Life Sciences' major shareholders? ENDRA Life Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include ICM Asset Management Inc. WA (6.37%). Company insiders that own ENDRA Life Sciences stock include David R Wells, Longboard Capital Advisors, Ll, Lou Basenese, Michael Harsh and Michael Milos Thornton. View institutional ownership trends for ENDRA Life Sciences. Which major investors are buying ENDRA Life Sciences stock? NDRA stock was purchased by a variety of institutional investors in the last quarter, including ICM Asset Management Inc. WA. Company insiders that have bought ENDRA Life Sciences stock in the last two years include David R Wells, Lou Basenese, Michael Harsh, and Michael Milos Thornton. View insider buying and selling activity for ENDRA Life Sciences. How do I buy shares of ENDRA Life Sciences? Shares of NDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ENDRA Life Sciences' stock price today? One share of NDRA stock can currently be purchased for approximately $0.90. How big of a company is ENDRA Life Sciences? ENDRA Life Sciences has a market capitalization of $12.99 million and generates $10,000.00 in revenue each year. The company earns $-13,310,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. ENDRA Life Sciences employs 11 workers across the globe. What is ENDRA Life Sciences' official website? The official website for ENDRA Life Sciences is www.endrainc.com. How can I contact ENDRA Life Sciences? ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The company can be reached via phone at 734-335-0468 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
